In a move that came as somewhat of a surprise given the Food and Drug Administration’s initial feelings on the matter, an advisory panel has recommended the approval of an anti-insomnia drug from Merck. The panel convened yesterday let the FDA know that the drug known as suvorexant appears to be both effective and safe for patients. They explained that doses recommended by Merck seemed appropriate and that insomnia sufferers appear to have been able to get sleep. What’s interesting is that this runs somewhat counter to the FDA’s own findings. Reports from earlier in the week suggested that the FDA was concerned about issues with extensive drowsiness after the effects of the drug were supposed to have worn off. Also troubling the FDA were reports about the onset of suicidal thoughts.
Click here for more about the panel’s thoughts.